Table 1.
All Participants (n=53) | Subset (n=37)a | |||||
---|---|---|---|---|---|---|
NOURISH-T (n=27) | EUC(n=26) | p-value | NOURISH-T(n=18) | EUC(n=19) | p-value | |
PCS Demographic Characteristics | ||||||
Age1 | 9.4 (2.5) | 10.5 (2.5) | .17 | 9.4 (2.7) | 11.6 (2.9) | .02* |
Gender - Male2 | 58.3 (14) | 45.8 (11) | .28 | 52.9% (n=9) | 40% (8) | .32 |
Race/Ethnicity | ||||||
Caucasian1 | 74.1 (20) | 65.4 (17) | .35 | 77.8 (14) | 73.7 (14) | .54 |
Hispanic1 | 14.8 (4) | 15.4 (4) | .63 | 16.7 (3) | 21.1 (4) | .53 |
Other/Unknown1 | 11.1 (3) | 19.2 (5) | .33 | 5.6 (1) | 5.3 (1) | .74 |
PCS Cancer Characteristics | ||||||
Age at Diagnosis2 | 4.6 (3.3) | 5.9 (3.5) | .22 | 4.6 (3.4) | 7.0 (3.0) | .04* |
Cancer Diagnosis | ||||||
Lymphoma or ALL1,3 | 55.6 (15) | 53.8 (14) | .56 | 55.6 (10) | 52.6 (10) | .56 |
Sarcoma1 | 7.4 (2) | 19.2 (5) | .19 | 11.1 (2) | 26.3 (5) | .23 |
Brain Cancer1 | 18.5 (5) | 7.7 (2) | .23 | 22.2 (4) | 10.5 (2) | .30 |
Other/Unknown1 | 18.5 (5) | 19.2 (5) | .61 | 11.1 (2) | 10.5 (2) | .68 |
BMI at Diagnosis2 | 73.7 (29.1) | 68.8 (31.4) | .68 | 88.0 (13.6) | 61.2 (29.2) | .01** |
Type of Treatment | ||||||
Chemotherapy Only1 | 50.0 (11) | 50.0 (11) | 1.0 | 46.7 (7) | 44.4 (8) | .59 |
Chemotherapy & Surgery1 | 18.2 (4) | 31.8 (7) | .24 | 20.0 (3) | 38.9 (7) | .21 |
Chemotherapy, Surgery, & Radiation1 | 31.8 (7) | 18.2 (4) | .24 | 33.3 (5) | 16.7 (3) | .24 |
Time off Treatment2 | 2.2 (1.5) | 2.2 (1.1) | .99 | 2.4 (1.0) | 1.7 (0.9) | .02* |
Late Medical Effects - No Limitations1 | 76.9 (10) | 83.3 (10) | .54 | 72.7 (8) | 81.8 (9) | .50 |
Caregiver Demographic Characteristics | ||||||
Age1 | 38.1 (7.5) | 42.5 (10.0) | .09 | 36.8 (6.1) | 42.6 (10.2) | .04* |
Gender - Male2 | 25.0 (6) | 25.0 (6) | .63 | 29.4 (5) | 25.0 (5) | .53 |
Annual Income - Over $60,0001 | 43.5 (10) | 54.2 (13) | .33 | 37.5 (6) | 55.0 (11) | .24 |
Marital Status - Married1 | 78.3 (18) | 83.3 (20) | .47 | 81.3 (13) | 90.9 (18) | .39 |
Education - College Degree + 1 | 43.5 (10) | 50.0 (12) | .44 | 50.0 (8) | 50.0 (10) | 1.0 |
Notes:
p<.05;
p<.01
Subset of participants with post-intervention data;
[mean(SD)];
[%(n)];
Acute Lymphoblastic Leukemia